» Articles » PMID: 35063732

Roles and Drug Development of METTL3 (methyltransferase-like 3) in Anti-tumor Therapy

Overview
Journal Eur J Med Chem
Specialty Chemistry
Date 2022 Jan 22
PMID 35063732
Authors
Affiliations
Soon will be listed here.
Abstract

Methyltransferase complex, such as METTL3/METTL14/WTP, catalyze N-methyladenosine (mA), which is the most abundant mRNA modification in mammals. Besides acting as a mA methyltransferase, METTL3 also regulates mRNA translation and other biological processes. Studies have identified numerous roles and molecular mechanisms associated with METTL3 in multiple biological processes especially in tumors in recent years. Furthermore, targeting METTL3 as an efficient therapeutic way for the treatment of different kinds of tumors has gained a lot of attention. However, these findings and researches have not been summarized. In this review, the most recent important roles of METTL3 in various tumors including acute myeloid leukemia, lung cancer, breast cancer, liver cancer, gastric cancer, pancreatic cancer, colorectal cancer, bladder cancer, prostate cancer and glioblastoma were systematically summarized. In addition, disclosed METTL3 inhibitors recently were also summarized and discussed for medicinal chemists investigating METTL3 inhibitors with different skeleton structures for the application of human cancer therapy.

Citing Articles

STM2457 impairs the proliferation of esophageal squamous cell carcinoma by activating DNA damage response through ATM-Chk2 axis.

Gao C, Yang H, Cheng J, He S, Yang Y, Xu L Med Oncol. 2025; 42(3):82.

PMID: 39985567 DOI: 10.1007/s12032-025-02634-3.


Exploring m6A modifications in gastric cancer: from molecular mechanisms to clinical applications.

Li P, Fang X, Huang D Eur J Med Res. 2025; 30(1):98.

PMID: 39940056 PMC: 11823136. DOI: 10.1186/s40001-025-02353-5.


METTL3: a multifunctional regulator in diseases.

Li N, Wei X, Dai J, Yang J, Xiong S Mol Cell Biochem. 2025; .

PMID: 39853661 DOI: 10.1007/s11010-025-05208-z.


METTL3 as a potential therapeutic target in gastric cancer.

Yu Z, Yang Y Front Oncol. 2024; 14:1483435.

PMID: 39678510 PMC: 11638058. DOI: 10.3389/fonc.2024.1483435.


Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.

Yu A, Fu L, Jing L, Wang Y, Ma Z, Zhou X Cell Death Differ. 2024; .

PMID: 39672819 DOI: 10.1038/s41418-024-01434-y.